Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry:development of a novel method by Fung, Francis H Y et al.
 http://acb.sagepub.com/
Annals of Clinical Biochemistry
 http://acb.sagepub.com/content/49/5/475
The online version of this article can be found at:
 
DOI: 10.1258/acb.2012.011257
 2012 49: 475Ann Clin Biochem
Francis H Y Fung, Jonathan C Y Tang, John P P Hopkins, John J Dutton, Lisa M Bailey and Andrew S Davison
novel method
Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a
 
 
Published by:
 http://www.sagepublications.com
On behalf of:
 
 Association for Clinical Biochemistry
 NVKC
 JSCC
 AACB
 can be found at:Annals of Clinical BiochemistryAdditional services and information for 
 
 
 
 
 http://acb.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://acb.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 What is This?
 
- Sep 1, 2012Version of Record >> 
 by guest on June 5, 2013acb.sagepub.comDownloaded from 
Original Article
Measurement of teicoplanin by liquid chromatography-tandem
mass spectrometry: development of a novel method
Francis H Y Fung1, Jonathan C Y Tang1, John P P Hopkins2, John J Dutton1, Lisa M Bailey1
and Andrew S Davison1
1Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool and Broadgreen University Hospital, 4th floor Duncan
Building, Liverpool L7 8XP; 2Waters MS Technology Centre, Micromass Atlas Park, Simons Way, Manchester M22 5PP, UK
Corresponding author: Francis H Y Fung. Email: Francis.Fung@nhs.net
Abstract
Background: Teicoplanin is an antibiotic used for the treatment of endocarditis, osteomyelitis, septic arthritis and methicillin-
resistant Staphylococcus aureus. Teicoplanin is emerging as a suitable alternative antibiotic to vancomycin, where their
trough serum levels are monitored by immunoassay routinely. This is the first report detailing the development of a liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring teicoplanin in patients’ serum.
Methods: An AcquityTM UPLC (ultra-pressure liquid chromatography) tandem mass spectrometer was used to measure tei-
coplanin concentrations in samples from patients, quality assurance schemes and quality control preparations. Ristocetin was
successfully implemented as a suitable internal standard. Ion suppression, linearity, stability, matrix effects, recovery, impre-
cision, lower limits of quantification and detection, interference and method comparison against immunoassay were all
assessed.
Results: Teicoplanin and ristocetin had elution times of 1.39 and 1.24 min, respectively. Ion suppression was shown to be neg-
ligible, and linear calibration curves (0–200 mg/mL) were consistently reproduced to have r2 values .0.99. Postextraction
stability was achieved up to 20 h, while matrix effects were minimal coupled with sample recovery of .93%. The lower
limit of quantification was 1 mg/mL, and 0.2 mg/mL was the lower limit of detection. Interference with other antibiotics was
dependent on the combination of drugs present in patients’ serum. A method comparison between immunoassay and LC-
MS/MS suggested a negative bias for tandem mass spectrometry.
Conclusions: This novel method of teicoplanin determination by LC-MS/MS is proven to be a robust protocol that is consist-
ent and reproducible. Clinicians searching for alternatives in therapeutic drug monitoring may have an additional option that is
potentially more accurate and specific.
Ann Clin Biochem 2012; 49: 475–481. DOI: 10.1258/acb.2012.011257
Introduction
Teicoplanin was ﬁrst isolated and identiﬁed from
Actinoplanes teichomyceticus, and was shown to be highly
active against Gram-positive pathogenic bacteria in 1978.1
Five closely related glycopeptides characterized by different
fatty acid chains of 10 and 11 carbon atoms comprise the
majority of teicoplanin found in vivo,2 while four minor
related compounds may also be present.3 Many groups
have investigated the biological properties of this peptide-
based compound, from the manner in which teicoplanin
inhibits peptidoglycan synthesis in the bacterial cell wall,4
its antibiotic activity and potency,5 to its mechanism of
action.6 Effective and safe in protection against staphylococ-
cal infections, including methicillin-resistant Staphylococcus
aureus (MRSA), teicoplanin has been used for the treatment
of endocarditis, osteomyelitis and septic arthritis.7
Vancomycin, a similar antibiotic, has historically been the
drug of choice for the treatment of infections caused by
MRSA; however, its potential nephrotoxicity is one of the
major limitations for its routine use. Some studies have
found an increased risk of renal failure following vancomy-
cin treatment,8 due to its effects on proximal tubular cells
where the antibiotic can accumulate inside lysosomes.
Teicoplanin has been shown to have essentially the same
efﬁcacy as vancomycin with some advantages, such as
once-daily bolus administration,9 intramuscular use,10
decreased occurrence of Red man syndrome11 and signiﬁ-
cantly lower adverse event rate of nephrotoxicity.12
Numerous studies have been carried out comparing the efﬁ-
cacy and safety of these two drugs, showing the potential
for teicoplanin as an alternative to vancomycin,13 and detail-
ing its safety proﬁle.14 There is evidence for disadvantages
Annals of Clinical Biochemistry 2012; 49: 475–481
 by guest on June 5, 2013acb.sagepub.comDownloaded from 
in teicoplanin administration, such as the possibility of
thrombocytopaenia15 and hypersensitivity, manifesting as
fever and chills.16 The majority of the available evidence
favours the bacteriolytic effect of teicoplanin17 and its
higher potency compared with vancomycin.18 In addition
to the similar cost of treatment,19 teicoplanin is emerging
as a suitable and appropriate alternative to vancomycin
for Staphylococcus infections.
Prevention of infection is one of the most important issues
that clinicians encounter in their daily routine. Teicoplanin
has been shown to be effective in the treatment of serious
Gram-positive infections in neonates,20 infants and chil-
dren,21,22 through to intensive care patients who require
constant monitoring.23 Patients undergoing total hip repla-
cement24 are also given doses of teicoplanin, as achievement
of rapid therapeutic serum concentrations improves the
chances of optimal clinical and bacteriological outcome.
Therapeutic drug monitoring (TDM) plays an important
role in the optimization of drug therapy, especially for
drugs with narrow therapeutic ranges. Since the introduc-
tion of home therapy and the use of teicoplanin in the com-
munity,25 clinicians have paid close attention to serum
concentrations of teicoplanin in their administration pro-
grammes. It is widely accepted that an optimal loading
dose followed by appropriate maintenance doses should
achieve trough serum concentrations of .25 mg/mL
rapidly and steadily, increasing the chances of full recovery
for the patient.
Pilot studies in pigs26 and rats27 have given rise to the
routine methods that are currently in use for the measure-
ment of teicoplanin in the clinical biochemistry laboratory.
The solid-phase enzyme receptor assay was most widely
used for TDM initially,28 until more rapid and accurate
assays became available. Some laboratories have used disc
diffusion and agar incorporation, with little success.29
Fluorescence polarization immunoassay (FPIA) was, and
still is, considered the gold standard by many for the deter-
mination of serum teicoplanin concentrations. The last
decade has seen the emergence of high-performance liquid
chromatography (HPLC) as a suitable alternative to
FPIA,30 a method that is comparatively faster and more
accurate than the traditional immunoassay.
Liquid chromatography-tandem mass spectrometry
(LC-MS/MS) is becoming widely accepted as an even
more accurate and reliable method for the determination
of biological components in a variety of matrices, exhibiting
higher levels of sensitivity and speciﬁcity compared with
other methods. There seems to be a lack of a methodology
for teicoplanin determination by LC-MS/MS, possibly due
to the size of this molecule6 and its ionization properties –
teicoplanin is a doubly-charged molecule with a molecular
weight (Mr) of 1881. Additionally, the heterogeneity of the
molecule in vivo,31 and the absence of an obvious (and
ﬁnancially suitable) internal standard, add to the difﬁculty
in measuring its concentration. Five isoforms (A2–1
through A2–5) comprise the majority of detectable teicopla-
nin, 93% of which are A2–2 and A2–3. The LC-MS/MS
method reported here is shown to be speciﬁc enough to
detect individual variations of this antibiotic, while consist-
ently utilizing ristocetin as a reliable internal standard to
determine detector response. This is the ﬁrst robust
method that has been developed for the measurement of tei-
coplanin in human serum that is suitable for routine use in a
clinical biochemistry laboratory.
Materials and method
Materials
Teicoplanin was purchased from Insight Biotechnology
(Middlesex, UK) and ristocetin was purchased from Sigma
(Dorset, UK). LC-MS/MS-grade methanol, acetonitrile
(ACN) and propan-2-ol were purchased from Fisher
Scientiﬁc (Loughborough, UK). In-house de-ionized water
(.18 MV) puriﬁed with a MilliQ water puriﬁcation system
(Millipore, France) was used. Drug-free serum (DFS) was pur-
chased from Bio-Rad (Hercules, CA, USA). Pooled serum was
obtained from anonymized patients’ samples. All samples
were stored at 2208C until analysis. Amikacin (Hospira,
Warwickshire, UK), gentamycin (Sanoﬁ-Aventis, Surrey,
UK), tobramycin (Teva, Buckinghamshire/Eastbourne, UK)
and vancomycin (Flynn Pharma, Dublin, Ireland) were all
kept sealed at room temperature until analysis.
Calibration standards and quality control material
A 1 mg/mL superstock solution of teicoplanin was prepared
in DFS, andworking calibrators weremade by dilution of the
stock solution into blank DFS to give calibrators with teico-
planin concentrations of 0, 12.5, 25, 50, 100 and 200 mg/mL.
Four quality control (QC) materials were prepared by
dilution of an independent stock of teicoplanin with DFS
(20 mg/mL) and pooled serum (50, 100, 200 mg/mL). A
1 mg/mL ristocetin internal standard superstock solution
was also prepared; a working concentration was used at
250 mg/mL.
Sample preparation
Serum samples, calibrators or QC samples (25 mL) and 50 mL
of internal standard (ristocetin) were protein-precipitated
by the addition of 200 mL of methanol. Tubes were vortex-
mixed vigorously for 30 s and centrifuged at 16,100 g for
5 min. The clear supernatant was transferred to glass mass
spectrometry sample vials and stored at 48C until analysis.
Liquid chromatography
Liquid chromatography was performed on a Waters
AcquityTM UPLC (ultra-pressure liquid chromatography)
system. Extracted sample (25 mL) was injected onto an
Acquity UPLC BEH (ethylene-bridged hybrid) C18 1.7 mm
(2.1  50 mm) column (Waters, Hertfordshire, UK) in
reversed-phase mode. Mobile phase A containing 1%
weight for volume (w/v) ammonium acetate and 0.1%
volume for volume (v/v) formic acid in de-ionized water
was introduced, coupled with the same composition but
dissolved in methanol for mobile phase B. Ninety-nine
percent mobile phase A was introduced from initial
sample injection, and switched to 1% mobile phase A at
................................................................................................................................................
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time 1.00, then 99% mobile phase A at time 1.45. Column
ﬂow rate was maintained at 600 mL/min and chromato-
graphy was performed at room temperature. Strong wash
consisting of 70% and 30% ACN and propan-2-ol, respect-
ively, were used in between sample injections.
Tandem mass spectrometry methods
Tandem mass spectrometry analyses were performed on a
Waters Premier system interfaced with a Z-spray electro-
spray ionization (ESI) source. Mobile phase delivery,
on-board auto-sampler and sample injection were moni-
tored by the MassLynx software of the mass spectrometer.
The ESI source was operated in the positive electrospray
ionization mode at a capillary voltage of 3.5 kV, a sample
cone voltage of 30 V, an extraction voltage of 2 V and a
radiofrequency lens voltage of 0.5 V. The collision energy
was optimized at 15 eV for teicoplanin and 25 eV for ristoce-
tin. Transitions were m/z 940.5 . 316.5 and m/z 1030.4 .
725 for teicoplanin and ristocetin, respectively. MassLynx
software (Version 4.1; Micromass, Manchester, UK) pro-
vided with the instrument running Windows XP was used
for instrument control, data acquisition, peak smoothing,
peak area integration and signal-to-noise determinations.
Method validation
Ion suppression
Ion suppression experiments were carried out by continu-
ous postcolumn infusion of teicoplanin (100 mg/mL)
directly into the mass spectrometer by a T-piece at a ﬂow
rate of 10 mL/min. Phosphate-buffered saline, water and
serum samples (n ¼ 5) were each injected into the mass
spectrometer and ion suppression/enhancement observed
and interpreted by any drop or increase in the total baseline
ion count around the retention time of the analyte.
Linearity
Linearity of the method was determined by analysing a set of
calibrators with concentrations ranging from 0 to 200 mg/mL.
QuanLynxTM software (Version 4.1; Waters) was used to plot
nominal values against the generated LC-MS/MS response,
deﬁned as teicoplanin:ristocetin peak area ratio. Linearity
of the calibrators were conﬁrmed if the correlation coefﬁcient
produced by weighted linear regression was .0.99.
Stability
Postextraction stability of both patient and QC samples were
assessed by continuous injections of a teicoplanin sample
over a 20-h period. The response of both teicoplanin and ris-
tocetin in each sample and the mean percentage change in
measured concentration was calculated. Different dilution
factors were tested (1:2 to 1:50) to assess the lower limit of
stable concentrations of analyte. Four different pH solutions
(2.7, 4.6, 6.5 and 8.6) were evaluated to determine an
optimal sample solution pH.
Matrix effects and recovery efficiency
Matrix effects of the methodology were determined by
preparing a teicoplanin-containing (100 mg/mL) aqueous
solution spiked with ristocetin (250 mg/mL), and comparing
the amount of teicoplanin measured against a teicoplanin-
containing serum solution spiked with ristocetin after
protein precipitation with methanol. Recovery was deter-
mined by comparing the amount of teicoplanin measured
both before and after protein-precipitated serum samples
were spiked with ristocetin (250 mg/mL).
Imprecision
Imprecision of the method was assessed by the analysis of
four QC samples at various concentrations (20, 50, 100
200 mg/mL). These samples were analysed 10 times each
within a single run to determine intra-assay imprecision,
and also analysed in separate batches (n ¼ 20) over a four-
week period to assess inter-assay imprecision. Both
standard deviation and coefﬁcient of variation (CV) were
calculated and used to determine the imprecision of the
method.
Limit of quantification and limit of detection
Lower limit of quantiﬁcation (LLOQ) and lower limit of
detection (LLOD) were determined by measuring a blank
10 times and calculating the percentage of deviation from
the target value and CV. LLOQ was assigned to the
lowest concentration with a CV, 20% and a signal-to-noise
ratio .10:1. LLOD was assigned to the lowest concentration
with a signal-to-noise ratio of .5:1.
Specificity
Interference of the assay was tested using four antibiotics
(amikacin, gentamycin, tobramycin and vancomycin).
All possible combinations of these four antibiotics with
teicoplanin were spiked (100 mg/mL) into serum samples
(n ¼ 3) and the response of each group was compared
against teicoplanin alone. These compounds were con-
sidered not to interfere in the teicoplanin assay if they did
not generate a signal in the chromatogram at the teicoplanin
elution time, and if the teicoplanin response was minimally
altered.
Method comparison
Method comparison was carried out with patients’ samples,
QC samples and EQA (external quality assurance) samples
that were previously assayed by FPIA, and all samples were
stored at 2808C until analysis by LC-MS/MS. Teicoplanin
samples (n ¼ 75) were analysed using this LC-MS/MS
method and the FPIA protocol on the Abbott TDx
(Abbott, Maidenhead, UK).
Results
Liquid chromatography and ion suppression studies
Teicoplanin and ristocetin had elution times of 1.39 and
1.24 min, respectively (Figure 1). A minimal background
signal was observed, highlighting the speciﬁcity of the
assay with speciﬁc teicoplanin and ristocetin transitions
and no observed interference in the region of interest. Ion
suppression experiments consistently showed a dip in base-
line ion count at 0.6 min, and the response increase began at
................................................................................................................................................
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one minute and persisted until 2.4 min (Figure 2). Various
retention times for teicoplanin and ristocetin were investi-
gated and ion suppression was determined to be absent as
both compounds eluted between 1 and 2.4 min, when
there was minimal signal interference.
Linearity
This teicoplanin assay was linear up to 200 mg/mL, as linear
regression analysis consistently gave r2 values .0.99.
Carryover between the lowest and highest calibrators was
,1%, evaluated by interspacing blanks. Ristocetin mass
spectrometer detector response was shown to be consistent
(CV, 5%), and a functional blank was employed in every
curve to determine the y-intercept. These results conﬁrmed
the validity of using calibrators made from drug-free
serum spiked with teicoplanin and ristocetin, as the region
of linearity spanned the entire therapeutic range of
25–75 mg/mL.
Stability
Postextraction stability of a teicoplanin sample (both
patients’ samples and QC material) spiked with the internal
standard was assessed by multiple injections over a 20-h
period. No systematic loss in sensitivity was observed
over this period for both teicoplanin and ristocetin peak
areas, and the CV of the peak area ratio was 3.1% (Figure 3).
Matrix effects and recovery efficiency
The mean matrix effect of the assay (n ¼ 10 for each par-
ameter) from the measured response of aqueous teicoplanin
samples and postextracted spiked samples was calculated
to be 7.9% (range: 6.6–9.1%). The mean recovery efﬁciency
(n ¼ 10 for each parameter) for this assay from the measured
response of extracted teicoplanin samples was calculated to
be 93.4% (range: 90–93.8%).
Imprecision
Four concentrations (20, 50, 100, 200 mg/mL) of teicoplanin
samples were used to determine the imprecision for both
intra-assay and inter-assay variations (Table 1). Intra-assay
CVs were less than 10% for the three lower concentrations,
while 200 mg/mL samples exhibited a CV of 11.3%. All
mean values were within 15% of the target concentration.
Inter-assay CVs were less than 10% for the three lower con-
centrations, while 200 mg/mL samples had a CV of 13.4%.
All mean values were within 12% of the target value.
Replicate samples were analysed, and LLOQ was deter-
mined as 1 mg/mL and LLOD as 0.2 mg/mL.
Interference
Potential interference with other antibiotics (amikacin, gen-
tamycin, tobramycin and vancomycin) was determined by
spiking teicoplanin samples with all possible combinations
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Figure 2 Typical ion suppression study from direct infusion. Trace rep-
resents the reduction in baseline ion count when teicoplanin and prepared
samples are injected into the mass spectrometer simultaneously. Transition A
represents a teicoplanin transition (1.09  105 cpm) and transition B rep-
resents a ristocetin transition (1.43  104 cpm)
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Figure 3 The detector stability of the assay. Injections of 25 mL were per-
formed over a 20-h period, and the individual response of teicoplanin and ris-
tocetin are plotted along with the response. The primary y-axis refers to the
peak areas of teicoplanin (V) and internal standard, ristocetin (B). The sec-
ondary y-axis refers to the response ratio of each injection (O, teicoplanin:ris-
tocetin peak-area ratio) and is plotted against each corresponding data point
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Figure 1 Typical chromatograms for teicoplanin and ristocetin. Transition A
is a typical teicoplanin peak with an elution time of 1.39 min and a detector
response of 1.09  105 cpm (200 mg/mL). Transition B is a typical ristocetin
peak with an elution time of 1.24 min and a detector response of 1.43 
104 cpm (2 mg/mL).
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of these four drugs (Table 2). CVs were ,10% for groups
that had only one drug in combination with teicoplanin.
The difference in abundance compared with teicoplanin
alone was more varied in multidrug combinations, and
combining vancomycin with teicoplanin caused a decrease
in teicoplanin detection by 23%. All four antibiotics (in
DFS) were injected into the mass spectrometer alone, and
no peaks were observed at the region of teicoplanin elution.
Method comparison
Altman–Bland analysis for FPIA (Abbott TDx) against
LC-MS/MS (Figure 4) showed the LC-MS/MS method
with a negative bias compared with the FPIA method.
The mean bias was 220.8 mg/mL. Linear regression analy-
sis (Figure 5) plotted the results generated from FPIA
against the new LC-MS/MS results, and a line of best ﬁt
illustrated the relationship between the two methods. The
majority of the data supported the trend that LC-MS/MS
reports lower values for the same sample analysed by
FPIA, where the r2 value was 0.86.
Discussion
LC-MS/MS has long been regarded as a powerful tool for
the quantitative determination of biological compounds in
a physiological matrix.32 Methods such as FPIA have tra-
ditionally been employed for measuring teicoplanin and
other antibiotics in serum, and as alternative techniques
became available, a number of laboratories have explored
the possibility of other methodologies.30 With the emer-
gence of teicoplanin as an alternative to vancomycin13 and
the recognized importance of trough serum concentration
monitoring in patients’ serum, the need for a mass spec-
trometry method for teicoplanin determination is now
apparent.
This is the ﬁrst report detailing the development of an
LC-MS/MS method for measuring teicoplanin in patients’
serum. Ristocetin was chosen as the internal standard due
to its similar structure and ionisation properties. A deuter-
ated teicoplanin compound would be ideal; however, this
was found to be cost-prohibitive. Initial suitability of both
compounds for LC-MS/MS was conﬁrmed as both teicopla-
nin and ristocetin co-eluted within 0.15 min of each other.
Transitions for both compounds were consistently speciﬁc
without interference in their respective regions of elution,
and ion suppression studies demonstrated that both peaks
were detected within the response increase. The lack of
ion suppression is crucial in an LC-MS/MS method, as sup-
pression has been shown to compromise detection selectiv-
ity.32 A calibration curve spanning the therapeutic range of
Table 1 Intra-assay and inter-assay standard deviation (SD) and
coefficient of variation (CV)
Target teicoplanin value (mg/mL) SD CV (%)
Within-batch (n ¼ 10)
20 0.8 4.0
50 3.0 6.3
100 3.7 4.4
200 22.4 11.3
Between-batch (n ¼ 20)
20 2.1 9.9
50 4.7 9.8
100 8.8 9.4
200 25.9 13.4
Teicoplanin samples at four concentrations (20, 50, 100 and 200 mg/mL)
were evaluated for their intra-assay (n ¼ 10) and inter-assay (n ¼ 20)
imprecision
Table 2 Variation of antibiotic combinations
TP A G T V AG AT AV
Variation (%) 100 101 116 117 77 112 123 77
CV (%) 5.9 7.8 5.8 3.2 8.4 6.6 2.8 1.6
GT GV TV AGT AGV GTV AGTV
Variation (%) 106 117 123 121 141 127 104
CV (%) 10.6 10.2 24.0 3.2 6.8 8.6 16.2
Teicoplanin (TP) samples spiked with amikacin (A), gentamycin (G),
tobramycin (T) and vancomycin (V) were compared against teicoplanin
alone, expressed as a percentage difference from 100. Coefficients of
variation (CVs) of each group of samples were also expressed as a
percentage
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Figure 4 Altman–Bland difference plot comparing the FPIA method (Abbott
TDx) and LC-MS/MS method. Dashed lines represent the 1 SD limits of agree-
ment for the mean difference between the two methods. Rectangle represents
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Figure 5 Linear regression graph comparing FPIA versus LC-MS/MS. The
relationship between results generated by FPIA and LC-MS/MS are illustrated
in this linear regression plot. The line of best fit generated a slope of 0.53 and
an r2 value of 0.86. Dashed line represents y ¼ x. FPIA, fluorescence polariz-
ation immunoassay; LC-MS/MS, liquid chromatography-tandem mass
spectrometry
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25–75 mg/mLwas demonstrated to be linear up to 200 mg/mL,
and can be consistently reproduced having an r2 value
.0.99. These preliminary steps to ensure both teicoplanin
and ristocetin can be reliably measured by LC-MS/MS are
of paramount importance so the performance characteristics
of the method are suitable and reliable for the intended
analytical applications.33
Repetitive injection of a teicoplanin sample over a 20-h
period was carried out to test the postextraction stability
of both the analyte of interest and the internal standard.
Postextracted samples displaying a high degree of stability
would be beneﬁcial to a clinical laboratory with multiple
assays set up on a given instrument. The response of teico-
planin:ristocetin was stable over this period of time.
Regarding the extraction efﬁciency of the protocol, matrix
effects were found to be ,10%, while the recovery efﬁciency
of this assay was shown to be .93%. This is a big advantage
in the properties of the method as a wide-ranging sample
matrix can be encountered, and effective recovery of
the analyte of interest would increase the reliability of the
assay. Intra-assay reproducibility experiments showed that
the CV for concentrations ranging 20–100 mg/mL were all
,7%. Similarly, the inter-assay CV for these limits spanning
the entire therapeutic range were all ,10%, highlighting
assay reliability.34 Toxicity is usually associated with teico-
planin levels .60 mg/mL;35 therefore, it was important to
establish consistency in this range of concentration.
A large amount of recent evidence suggests the suitability
of teicoplanin as a replacement for vancomycin due to its
similar antibiotic activity and lower potential for nephro-
toxicity.13,14 It is unlikely that patients are administered tei-
coplanin in conjunction with vancomycin, tobramycin,
gentamycin or amikacin; nevertheless, an inhibition study
was carried out evaluating all possible combinations of
these antibiotics and their effects on teicoplanin measure-
ment in the mass spectrometer. As shown in Table 2, vanco-
mycin has the potential of lowering the response of
teicoplanin detection, possibility due to their molecular
similarity in sharing the same glycopeptide core. This exper-
iment highlights the possible interference of vancomycin,
and clinicians should be aware if there is a chance of admin-
istering both antibiotics simultaneously, although this scen-
ario is unlikely since teicoplanin is given as an alternative to
vancomycin.
Different methods for measuring the same analyte have
been known to produce results that vary in their relation-
ship to the outcome of the patient.29 This new assay using
LC-MS/MS was compared with FPIA using QC material,
EQA samples and past patients’ samples to decipher the
fundamental differences in measuring teicoplanin using
two different protocols. Altman–Bland plots and linear
regression graphs both show the negative bias that exists
for teicoplanin measurement by mass spectrometry. FPIA
utilizes a polyclonal antibody that potentially measures all
isoforms of teicoplanin, while allowing for the possibility
of cross-reactivity that is antibody dependent. The new
LC-MS/MS method reported here is speciﬁc for the A2–2
and A2–3 variations, which accounts for 93% of total teico-
planin found in serum (personal communication, Santa
Cruz Biotechnology, Santa Cruz, CA, USA). More
importantly, consistency appeared to be high within the
therapeutic range, where the majority of drug-monitored
serum levels occur and are maintained. Rarely do serum tei-
coplanin concentrations rise above 100 mg/mL, in which
case drastic action has to be taken to avoid any permanent
hepatic or nephritic damage.
In conclusion, this is the ﬁrst time a novel method of
monitoring serum teicoplanin concentrations by LC-MS/
MS has been reported. The methodology has been devel-
oped, optimized and evaluated according to widely
accepted protocols and guidelines.33,34 There are a number
of advantages in this method: small sample volume,
minimal sample preparation steps, rapid analysis and accu-
rate read-outs. There appears to be differences between
results generated by FPIA and LC-MS/MS. While the proto-
col reported here is robust, continual evaluation will add
further conﬁrmation to the LC-MS/MS methodology.
Measuring teicoplanin by mass spectrometry has the poten-
tial to dramatically improve the reliability in monitoring this
antibiotic, whose trough serum concentrations have to be
quickly determined to establish the subsequent dosage con-
centration.36 This novel method provides an additional
option for medical professionals involved in TDM, one
that will hopefully become the new gold standard in
serum teicoplanin determination.
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